FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:1239-1245 November 10, 1988 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Amplification of the neu proto-oncogene in breast cancer has been reported to correlate with the presence of lymph-node metastases and with a poor prognosis. We describe a method for the immunohistochemical detection of overexpression of neu protein on formalin-fixed paraffin-embedded tissue, with the use of two different monoclonal antibodies. In a group of tumors with a known neu-gene copy number, intense membrane staining of tumor cells was present in all tumors with neu-gene amplification. Of 189 tumors from patients with Stage II breast cancer, 27 (14 percent) had neu-membrane staining. Neu overexpression was associated with larger tumor size (P = 0.006) but not with lymph-node involvement. Neu-protein expression in lymph-node metastases was the same as its expression in primary tumors. Among the patients with neu overexpression (median follow-up, 37 months), disease-free survival was not significantly shorter; overall survival was reduced significantly in these patients (P = 0.042), but this reduction did not remain significant after adjustment for tumor size. Of 45 ductal carcinomas in situ, 19 (42 percent) had neu-membrane staining. These 19 were all of the large-cell, comedo growth type. None of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type had neu overexpression. We conclude that neu overexpression may be an early step in the development of a distinct histologic type of carcinoma of the breast, but we could find no association of overexpression with lymph-node status or tumor recurrence.

Source Information

Department of Pathology, Netherlands Cancer Institute, Amsterdam.

This article has been cited by other articles:

• Dourdin, N., Schade, B., Lesurf, R., Hallett, M., Munn, R. J., Cardiff, R. D., Muller, W. J. (2008). Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis. Cancer Res. 68: 2122-2131 [Abstract] [Full Text]  
• Vincent-Salomon, A., Lucchesi, C., Gruel, N., Raynal, V., Pierron, G., Goudefroye, R., Reyal, F., Radvanyi, F., Salmon, R., Thiery, J.-P., Sastre-Garau, X., Sigal-Zafrani, B., Fourquet, A., Delattre, O., for the breast cancer study group of the Institut, (2008). Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast. Clin. Cancer Res. 14: 1956-1965 [Abstract] [Full Text]  
• Allred, D. C., Wu, Y., Mao, S., Nagtegaal, I. D., Lee, S., Perou, C. M., Mohsin, S. K., O'Connell, P., Tsimelzon, A., Medina, D. (2008). Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution. Clin. Cancer Res. 14: 370-378 [Abstract] [Full Text]  
• Provinciali, M., Papalini, F., Orlando, F., Pierpaoli, S., Donnini, A., Morazzoni, P., Riva, A., Smorlesi, A. (2007). Effect of the Silybin-Phosphatidylcholine Complex (IdB 1016) on the Development of Mammary Tumors in HER-2/neu Transgenic Mice. Cancer Res. 67: 2022-2029 [Abstract] [Full Text]  
• Schmidt, M. K., Tollenaar, R. A.E.M., de Kemp, S. R., Broeks, A., Cornelisse, C. J., Smit, V. T.H.B.M., Peterse, J. L., van Leeuwen, F. E., Van 't Veer, L. J. (2007). Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation. JCO 25: 64-69 [Abstract] [Full Text]  
• Kreike, B., Halfwerk, H., Kristel, P., Glas, A., Peterse, H., Bartelink, H., van de Vijver, M. J. (2006). Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.. Clin. Cancer Res. 12: 5705-5712 [Abstract] [Full Text]  
• Woditschka, S., Haag, J. D., Waller, J. L., Monson, D. M., Hitt, A. A., Brose, H. L., Hu, R., Zheng, Y., Watson, P. A., Kim, K., Lindstrom, M. J., Mau, B., Steele, V. E., Lubet, R. A., Gould, M. N. (2006). Neu-Induced Retroviral Rat Mammary Carcinogenesis: A Novel Chemoprevention Model for Both Hormonally Responsive and Nonresponsive Mammary Carcinomas.. Cancer Res. 66: 6884-6891 [Abstract] [Full Text]  
• Rodenhuis, S., Bontenbal, M., van Hoesel, Q. G. C. M., Smit, W. M., Nooij, M. A., Voest, E. E., van der Wall, E., Hupperets, P., van Tinteren, H., Peterse, J. L., van de Vijver, M. J., de Vries, E. G. E., for the Netherlands Working Party on Autologous Tr, (2006). Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17: 588-596 [Abstract] [Full Text]  
• Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., Van Limbergen, E., Berteloot, P., Amant, F., Vergote, I., Christiaens, M. R. (2005). Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 16: 1755-1761 [Abstract] [Full Text]  
• Huang, H J, Neven, P, Drijkoningen, M, Paridaens, R, Wildiers, H, Van Limbergen, E, Berteloot, P, Amant, F, Vergote, I, Christiaens, M R (2005). Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J. Clin. Pathol. 58: 611-616 [Abstract] [Full Text]  
• Sakai, Y., Morrison, B. J., Burke, J. D., Park, J.-M., Terabe, M., Janik, J. E., Forni, G., Berzofsky, J. A., Morris, J. C. (2004). Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. Cancer Res. 64: 8022-8028 [Abstract] [Full Text]  
• Osborne, C., Wilson, P., Tripathy, D. (2004). Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications. The Oncologist 9: 361-377 [Abstract] [Full Text]  
• Leonard, G. D., Swain, S. M. (2004). Ductal Carcinoma In Situ, Complexities and Challenges. JNCI J Natl Cancer Inst 96: 906-920 [Abstract] [Full Text]  
• Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2004). Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein. Mol. Cell. Proteomics 3: 379-398 [Abstract] [Full Text]  
• Tedesco, K.L., Thor, A.D., Johnson, D.H., Shyr, Y., Blum, K.A., Goldstein, L.J., Gradishar, W.J., Nicholson, B.P., Merkel, D.E., Murrey, D., Edgerton, S., Sledge, G.W. Jr (2004). Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial. JCO 22: 1071-1077 [Abstract] [Full Text]  
• Manor, D., Shmidt, E. N., Budhu, A., Flesken-Nikitin, A., Zgola, M., Page, R., Nikitin, A. Yu., Noy, N. (2003). Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II. Cancer Res. 63: 4426-4433 [Abstract] [Full Text]  
• Renard, V., Sonderbye, L., Ebbehoj, K., Rasmussen, P. B., Gregorius, K., Gottschalk, T., Mouritsen, S., Gautam, A., Leach, D. R. (2003). HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice. J. Immunol. 171: 1588-1595 [Abstract] [Full Text]  
• Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., Bloom, K. J. (2003). The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 8: 307-325 [Abstract] [Full Text]  
• Rodenhuis, S., Bontenbal, M., Beex, L. V.A.M., Wagstaff, J., Richel, D. J., Nooij, M. A., Voest, E. E., Hupperets, P., van Tinteren, H., Peterse, H. L., TenVergert, E. M., de Vries, E. G.E., the Netherlands Working Party on Autologous Transp, (2003). High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. NEJM 349: 7-16 [Abstract] [Full Text]  
• Arteaga, C. L., Baselga, J. (2003). Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice. Clin. Cancer Res. 9: 1579-1589 [Full Text]  
• Kagan, B. L., Henke, R. T., Cabal-Manzano, R., Stoica, G. E., Nguyen, Q., Wellstein, A., Riegel, A. T. (2003). Complex Regulation of the Fibroblast Growth Factor-binding Protein in MDA- MB-468 Breast Cancer Cells by CCAAT/Enhancer-binding Protein {beta}. Cancer Res. 63: 1696-1705 [Abstract] [Full Text]  
• DiGiovanna, M. P., Chu, P., Davison, T. L., Howe, C. L., Carter, D., Claus, E. B., Stern, D. F. (2002). Active Signaling by HER-2/neu in a Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates. Cancer Res. 62: 6667-6673 [Abstract] [Full Text]  
• Lee, S., Yang, W., Lan, K.-H., Sellappan, S., Klos, K., Hortobagyi, G., Hung, M.-C., Yu, D. (2002). Enhanced Sensitization to Taxol-induced Apoptosis by Herceptin Pretreatment in ErbB2-overexpressing Breast Cancer Cells. Cancer Res. 62: 5703-5710 [Abstract] [Full Text]  
• Singletary, S. E., Atkinson, E. N., Hoque, A., Sneige, N., Sahin, A. A., Fritsche, H. A. Jr., Lotan, R., Lu, T., Hittelman, W. N., Bevers, T. B., Stelling, C. B., Lippman, S. M. (2002). Phase II Clinical Trial of N-(4-Hydroxyphenyl)retinamide and Tamoxifen Administration before Definitive Surgery for Breast Neoplasia. Clin. Cancer Res. 8: 2835-2842 [Abstract] [Full Text]  
• Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., Bernstein, L. (2002). Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens. JCO 20: 3095-3105 [Abstract] [Full Text]  
• Hoque, A., Sneige, N., Sahin, A. A., Menter, D. G., Bacus, J. W., Hortobagyi, G. N., Lippman, S. M. (2002). HER-2/neu Gene Amplification in Ductal Carcinoma In Situ of the Breast. Cancer Epidemiol. Biomarkers Prev. 11: 587-590 [Abstract] [Full Text]  
• Chan, K. C., Knox, W. F., Gee, J. M., Morris, J., Nicholson, R. I., Potten, C. S., Bundred, N. J. (2002). Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition on Epithelial Proliferation in Normal and Premalignant Breast. Cancer Res. 62: 122-128 [Abstract] [Full Text]  
• Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., Borgs, M. (2001). Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial. JCO 19: 3808-3816 [Abstract] [Full Text]  
• Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001). Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy. Clin. Cancer Res. 7: 1497-1504 [Abstract] [Full Text]  
• Tolcher, A. W. (2001). Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel. The Oncologist 6: 40-44 [Abstract] [Full Text]  
• Braun, S., Schlimok, G., Heumos, I., Schaller, G., Riethdorf, L., Riethmüller, G., Pantel, K. (2001). erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients. Cancer Res. 61: 1890-1895 [Abstract] [Full Text]  
• Carr, J. A., Havstad, S., Zarbo, R. J., Divine, G., Mackowiak, P., Velanovich, V. (2000). The Association of HER-2/neu Amplification With Breast Cancer Recurrence. Arch Surg 135: 1469-1474 [Abstract] [Full Text]  
• Pich, A., Margaria, E., Chiusa, L. (2000). Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival. JCO 18: 2948-2956 [Abstract] [Full Text]  
• Gandhi, A., Holland, P. A., Knox, W. F., Potten, C. S., Bundred, N. J. (2000). Effects of a Pure Antiestrogen on Apoptosis and Proliferation within Human Breast Ductal Carcinoma in Situ. Cancer Res. 60: 4284-4288 [Abstract] [Full Text]  
• Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., Heiss, M. M. (2000). c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems. JCO 18: 2201-2209 [Abstract] [Full Text]  
• Schelfhout, V. R. J., Coene, E. D., Delaey, B., Thys, S., Page, D. L., De Potter, C. R. (2000). Pathogenesis of Paget's Disease: Epidermal Heregulin-{alpha}, Motility Factor, and the HER Receptor Family. JNCI J Natl Cancer Inst 92: 622-628 [Abstract] [Full Text]  
• Elkhuizen, P. H. M., van Slooten, H.-J., Clahsen, P. C., Hermans, J., van de Velde, C. J. H., van den Broek, L. C. J. M., van de Vijver, M. J. (2000). High Local Recurrence Risk After Breast-Conserving Therapy in Node-Negative Premenopausal Breast Cancer Patients Is Greatly Reduced by One Course of Perioperative Chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. JCO 18: 1075-1075 [Abstract] [Full Text]  
• Stark, A., Hulka, B. S., Joens, S., Novotny, D., Thor, A. D., Wold, L. E., Schell, M. J., Melton, L. J. III, Liu, E. T., Conway, K. (2000). HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer. JCO 18: 267-267 [Abstract] [Full Text]  
• Liu, W.-M., Guerra-Vladusic, F. K., Kurakata, S., Lupu, R., Kohwi-Shigematsu, T. (1999). HMG-I(Y) Recognizes Base-unpairing Regions of Matrix Attachment Sequences and Its Increased Expression Is Directly Linked to Metastatic Breast Cancer Phenotype. Cancer Res. 59: 5695-5703 [Abstract] [Full Text]  
• Davies, B. R., Platt-Higgins, A. M., Schmidt, G., Rudland, P. S. (1999). Development of Hyperplasias, Preneoplasias, and Mammary Tumors in MMTV-c-erbB-2 and MMTV-TGF{alpha} Transgenic Rats. Am. J. Pathol. 155: 303-314 [Abstract] [Full Text]  
• Scorilas, A., Yotis, J., Pateras, C., Trangas, T., Talieri, M. (1999). Predictive Value of c-erbB-2 and Cathepsin-D for Greek Breast Cancer Patients Using Univariate and Multivariate Analysis. Clin. Cancer Res. 5: 815-821 [Abstract] [Full Text]  
• Kersemaekers, A.-M. F., Fleuren, G. J., Kenter, G. G., Van den Broek, L. J. C. M., Uljee, S. M., Hermans, J., Van de Vijver, M. J. (1999). Oncogene Alterations in Carcinomas of the Uterine Cervix: Overexpression of the Epidermal Growth Factor Receptor Is Associated with Poor Prognosis. Clin. Cancer Res. 5: 577-586 [Abstract] [Full Text]  
• Ross, J. S., Fletcher, J. A. (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells 16: 413-428 [Abstract] [Full Text]  
• Ross, J. S., Fletcher, J. A. (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. The Oncologist 3: 237-252 [Abstract] [Full Text]  
• Tanner, M. M., Karhu, R. A., Nupponen, N. N., Borg, A., Baldetorp, B., Pejovic, T., Ferno, M., Killander, D., Isola, J. J. (1998). Genetic Aberrations in Hypodiploid Breast Cancer : Frequent Loss of Chromosome 4 and Amplification of CyclinD1 Oncogene. Am. J. Pathol. 153: 191-199 [Abstract] [Full Text]  
• Gattuso, P., Bloom, K., Yaremko, L., Borok, R., Cobleigh, M., Madsen, K., Gould, V. E., Reddy, V. (1998). Marker Panel Predictive of Lymph Node Metastasis in Young Patients with Breast Carcinoma. INT J SURG PATHOL 6: 55-60 [Abstract]  
• Chabner, E., Schnitt, S., Harris, J. (1997). Current Management of Patients with Ductal Carcinoma-in-Situ. The Oncologist 2: 76-82 [Abstract] [Full Text]  
• Cirisano, F. D., Karlan, B. Y. (1996). The Role of the HER-2/neu Oncogene in Gynecologic Cancers. Reproductive Sciences 3: 99-105 [Abstract]  
• Guy, C. T., Cardiff, R. D., Muller, W. J. (1996). Activated neu Induces Rapid Tumor Progression. J. Biol. Chem. 271: 7673-7678 [Abstract] [Full Text]  
• Kacinski, B. M., Nguyen, J., Carter, D. (1995). Expression of neu Antigen in Normal Lactating and Prepartum Mammary Epithelial Cells. Reproductive Sciences 2: 51-56 [Abstract]  
• Gattuso, P., Reddy, V. B., Green, L. K., Castelli, M. J., Wick, M. R. (1995). Prognostic Factors for Carcinoma of the Male Breast. INT J SURG PATHOL 2: 199-206 [Abstract]  
• De Corte, V, De Potter, C, Vandenberghe, D, Van Laerebeke, N, Azam, M, Roels, H, Mareel, M, Vandekerckhove, J (1994). A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells. J. Cell Sci. 107: 405-416 [Abstract]  
• Swain, S. M. (1993). In Situ or Localized Breast Cancer -- How Much Treatment Is Needed?. NEJM 328: 1633-1634 [Full Text]  
• Slamon, D., Godolphin, W, Jones, L., Holt, J., Wong, S., Keith, D., Levin, W., Stuart, S., Udove, J, Ullrich, A, et, al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712 [Abstract]  
• Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., Muller, W. J. (2000). Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 97: 3444-3449 [Abstract] [Full Text]